Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Poniard Pharmaceuticals Inc: Premium Company Profile

Published by: Datamonitor

Published: Apr. 22, 2008 - 41 Pages


Table of Contents


Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products and Services
Picoplatin
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
In-house Pipeline
Picoplatin
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Picoplatin for small cell lung cancer
Weaknesses
Discontinued product candidates
Termination of agreement with Janssen Pharmaceutica
Opportunities
Market for anti-cancer drugs
Threats
Uncertainty in the coverage and reimbursement status
Lengthy and expensive regulatory process
Value Chain Analysis
Overview
Discovery and Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Jerry McMahon
Ronald A Martell
Robert S Basso
Frederick B Craves
E Rolland Dickson
Carl S Goldfischer
Robert M Littauer
Nicholas J Simon
David R Stevens
Caroline M Loewy
Robert De Jager
David A Karlin
Cheni Kwok
Anna Lewak Wight
Financial and Operational Overview
Financial and Operational Overview
APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Poniard - Key Facts
Table 2: Poniard - Locations and Subsidiaries
Table 3: Poniard - Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Poniard - Key Events Impacting Share Price Performance
Table 5: Poniard - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: Poniard - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Poniard - Balance Sheet, 2002-2006 ($ Mn)
Table 8: Poniard - Cash Flow, 2002-2006 ($ Mn)
Table 9: Poniard - In-house Pipeline Products
Table 10: Poniard - Forecast Sales, 2006-2010 ($ Mn)
Table 11: Poniard - Key Competitors
Table 12: Poniard - Key Suppliers
Table 13: Poniard - Key Shareholders
Table 14: Poniard - SWOT Analysis Summary
Table 15: Poniard - Value Chain Analysis
Table 16: Poniard - Key Employees
Table 17: Poniard - Financial and Operational Overview
List of Figures
Figure 1: Poniard - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)


Abstract

Introduction

Poniard Pharmaceuticals, formerly known as NeoRx Corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapy products. The company’s lead product candidate, Picoplatin, is currently in Phase III clinical development for small cell lung cancer and offers a huge opportunity for the company to achieve its first commercial success.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company’s product pipeline includes single product, Picoplatin, a new generation cytotoxic platinum compound that provides a differentiated spectrum of activity and an improved safety profile. Picoplatin is being developed for small cell lung cancer (Phase III), colorectal cancer (Phase II), and prostate cancer (Phase II). The company does not have any significant ongoing revenue sources till date. On occasion, the company derives revenues from the sale or licensing of its patented technologies and from government grants. The company’s total revenues decreased from $11.1 million in 2002 to absolute zero in 2006. For the fiscal 2006, the company did not recognize any revenues due to non-recognition of any royalties for licensed intellectual property as recognized in 2004 and 2005 from Boston Scientific.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Please note: This is delivered as a Zip file.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008